Impact of Sars-CoV-2 prophylaxis with tixagevimab-cilgavimab in high-risk patients with B-cell malignancies: a single-center retrospective study.

Impact of Sars-CoV-2 prophylaxis with tixagevimab-cilgavimab in high-risk patients with B-cell malignancies: a single-center retrospective study.

Severe Acute Respiratory Syndrome CoronaVirus‐2 (SARS‐CoV‐2) infection can result in different clinical manifestations (COVID-19), starting from asymptomatic disease to life threatening respiratory insufficiency. Onco-haematologic patients are at higher risk to develop severe COVID-19. In particula...

Full description

Bibliographic Details
Main Authors: Giovanni Manfredi Assanto, Matteo Totaro, Poggiali Rebecca, Delli Paoli Adele, Annechini Giorgia, D’Elia Gianna Maria, Aji Francesco, Petrucci Luigi, Fazio Francesca, Del Giudice Ilaria, Martelli Maurizio, Micozzi Alessandra, Giuseppe Gentile
Format: Article
Language:English
Published: Mattioli1885 2023-10-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Subjects:
B-cell malignancies
COVID-19
tixagevimab-cilgavimab
Pre-exposure prophylaxis
Online Access:http://www.mjhid.org/index.php/mjhid/article/view/5415

Internet

http://www.mjhid.org/index.php/mjhid/article/view/5415

Similar Items